News
Warfarin Discontinuation Linked to Increased Risk of Death, Adverse Events in Very Elderly
Physician-perceived frailty and low life expectancy are the main reasons for warfarin discontinuation in elderly patients
Your search for Warfarin returned 17 results
News
Same-day genetic testing service available for safer warfarin dosing
Machaon Diagnostics has launched a same-day genetic testing service for patients that have been prescribed warfarin (Coumadin, from Bristol-Myers Squibb).
News
Drug Interaction Possible When HCV Regimens Added to Warfarin
A retrospective cohort study in the Annals of Pharmacotherapy found a clinically significant decrease in warfarin dose-response with concurrent hepatitis C treatments, especially with ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV-PTV/r-DSV).
News
Impact of Oral Anticoagulants on Renal Outcomes Compared
Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
News
Anticoagulation Therapy Appears to Be Safe After TAVI
After transcatheter aortic valve implantation (TAVI) there is no increased risk of bleeding or other adverse outcomes for those patients who have an indication for anticoagulant therapy.
News
Long-Term Warfarin in AFib Patients May Up Dementia Risk
Patients with atrial fibrillation taking long-term warfarin had higher rates of dementia than non-atrial fibrillation patients, a study presented at the Heart Rhythm Society's 37th Annual Scientific Sessions has found.
Drug News
AAN: Anticoagulation with Nonvalvular Atrial Fibrillation
Most people with nonvalvular atrial fibrillation (NVAF) should be taking oral anticoagulants to prevent stroke.
Drugs in the Pipeline
Phase 3 study of rivaroxaban for the treatment of stroke associated with atrial fibrillation (AF)
Johnson & Johnson Pharmaceutical Research & Development announced results from its Phase 3 study of rivaroxaban in non-valvular atrial fibrillation (AF) patients to reduce the risk of stroke and non-CNS systemic embolism.
Drugs in the Pipeline
BLA Accepted for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
CSL Behring announced that the FDA has accepted for standard review its Biologics License Application (BLA) for a human 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of vitamin K-antagonist therapy (eg, warfarin) in patients with acute major bleeding.
News
Warfarin Patients With Head Trauma Need Second CT Scan
For patients on warfarin with minor head trauma who have an initial negative computed tomography (CT) scan, 24-hour observation followed by an additional CT scan identifies the majority of cases of delayed bleeding.
